Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Myovant Sciences Ltd. (MYOV) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/10/2023 8-K Appointed a new director
Docs: "BERMUDA THE COMPANIES ACT 1981 MEMORANDUM OF ASSOCIATION OF COMPANY LIMITED BY SHARES",
"AMENDED AND RESTATED BYE-LAWS OF Myovant Sciences Ltd. Bermuda Office Canon’s Court 22 Victoria Street Hamilton HM 12 Bermuda CONTENTS Bye-Law Page Interpretation 1 General Meetings 3 Notice of General Meetings 3 Proceedings at General Meetings 4 Voting 5 Proxies and Corporate Representatives 6 Written Resolutions of the Sole Member 8 Appointment and Removal of Directors 8 Register of Directors and Officers 9 Resignation and Disqualification of Directors 9 Alternate Directors 9 Directors’ Fees and Expenses 10 Directors’ Interests 10 Role and Powers of the Board 11 Proceedings of the Board 12 Officers 14 Secretary and Resident Representative 14 Issue of Shares 14 Purchase of Shares 15 Variation of Share Rights 15 Share Certificates 15 Non-Recognition of Trusts 16 Lien 16 Calls on Shares 17 ...",
"NEW YORK and BASEL, Switzerland, March 10, 2023"
03/01/2023 8-K Quarterly results
01/26/2023 8-K Quarterly results
Docs: "Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022"
10/26/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
10/03/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
Docs: "Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022"
05/10/2022 8-K Quarterly results
03/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No.1 to Myovant Sciences Ltd. 2020 Inducement Plan"
01/26/2022 8-K Quarterly results
Docs: "Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates"
01/10/2022 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021"
11/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/26/2021 8-K Quarterly results
Docs: "Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates"
08/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/28/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates"
07/07/2021 8-K Other Events  Interactive Data
06/04/2021 8-K Quarterly results
05/26/2021 8-K Quarterly results
05/19/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/04/2021 8-K Quarterly results
12/28/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
12/18/2020 8-K Other Events  Interactive Data
11/12/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020"
09/17/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/11/2020 8-K Quarterly results
05/18/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended - Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Phase 3 SPIRIT 1study expected in the second quarter of calendar year 2020 - New Drug Application submitted for relugolix monotherapy tablet for men with advanced prostate cancer, with castration resistance-free survival results expected in the third quarter of calendar year 2020 - Marketing Authorization Application for relugolix combination tablet for women with uterine fibroids submitted and currently under evaluation by the European Medicines Agency, with NDA submission expected in May 2020 - Strategic partnership with G..."
05/08/2020 8-K Quarterly results
02/10/2020 8-K Quarterly results
12/30/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
10/31/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy